haematological malignancies. 8, 10, 11 Moreover, some miRNAs can also down-regulate the expression of DKK3 at the post-transcriptional level in some cancers. 9, 12, 13 Indeed, in support of this, our previous studies have shown that miR-708 down-regulates the expression and secretion of DKK3-induced activation of Wnt/b-catenin pathways in B-ALL cell lines through direct targeting of the 3 0 -UTR of DKK3.
14 To determine whether transcription factors lead to DKK3 silencing, we analysed the promoter regions of DKK3 by bioinformatics and found multiple binding sites for MYCN, which indicates that the expression of DKK3 may be down-regulated by MYCN at the transcriptional level.
MYCN, a member of the MYC proto-oncogene family, encodes a nuclear transcriptional activator/repressor phosphoprotein that functions in the direct up-or down-regulation of genes via promoter binding. MYCN also acts through indirect pathways to control cell proliferation, apoptosis and differentiation; MYCN is also extensively involved in oncogenesis. [15] [16] [17] [18] MYCN is overexpressed in many malignancies, such as retinoblastoma, medulloblastoma and neuroblastoma, and MYCN overexpression is correlated with increased growth potential and poor prognosis. [19] [20] [21] However, few studies to date have shown that MYCN can promote cell proliferation and inhibit the activity of tumour suppressor gene-related signalling pathways that participate in adult B-ALL, which cumulatively lead to a poor prognosis.
Here, we show that the MYCN mRNA level is negatively corre- 
| MATERIALS AND METHODS

| Patient samples
| Cell culture
The human B-ALL cell lines Nalm6 and BALL-1 were used in this study. The characteristics and the culture conditions are described in the Supporting information.
| Bisulphite sequencing PCR
We performed BSP as previously described. 14 Five to ten clones from each sample were subjected to cycle sequencing (PE Applied Biosystems, Warrington, UK) and analysed using an ABI 310 sequencer (Applied Biosystems, Foster City, CA, USA). The primers used for BSP and the details of these experiments are given in the Supporting information.
| Dual-luciferase gene reporter assay
Luciferase assays were performed in Nalm6 cells. Luciferase activity was measured in the transfected cells using a Dual-Luciferase Reporter Assay System (Promega, WI, USA).
| Chromatin immunoprecipitation (ChIP) assay
ChIP analysis was performed according to the manufacturer's instructions (ChIP kit; Upstate Biotechnology, Waltham, USA) using an anti-MYCN antibody (Becton Dickinson Pharmingen, San Diego, USA). DKK3 promoter-specific primers and detailed methods are included in the Supporting information.
| Cell proliferation analysis
Cell proliferation was assayed using the Cell Counting Kit-8 method (CCK-8; Sigma-Aldrich).
| Flow cytometric analysis of the cell cycle and apoptosis
For the cell cycle analysis, the cells were stained with propidium iodide (PI, Sigma-Aldrich). The apoptosis analysis was performed using Annexin V-FITC/PI according to the manufacturer's protocol (Sigma-Aldrich).
| In vivo experiments
In vivo experiments performed in NOD/SCID mice are described in the Supporting information.
| Statistical analyses
The data are presented as the means AE SD. Comparisons of two or more data sets were analysed using one-way analysis of variance 3.2 | MYCN directly binds to the DKK3 promoter but has no effect on DKK3 promoter methylation To elucidate the relationship between MYCN and DKK3 in adult B-ALL, we constructed firefly luciferase reporters containing the DKK3 gene promoter region and predicted MYCN binding sites ( Figure 2A ).
Co-transfection of Nalm6 cells with a MYCN overexpression plasmid greatly reduced the luciferase activity driven by the DKK3 promoter region ( Figure 2B ). Next, a ChIP analysis was performed to further investigate whether MYCN binds to the promoter region of DKK3 in Nalm6 cells. As shown in Figure 2D , DNA sequence fragments from the DKK3 promoter onto which MYCN was recruited were amplified by PCR using specific primers. In addition, MYCN overexpression significantly decreased the DKK3 mRNA and protein levels and MYCN siRNA increased DKK3 mRNA and protein expression in Nalm6 and BALL-1 cells ( Figure 2E ,F). These data indicated that MYCN binds directly to the promoter region of DKK3 and significantly down-regulates DKK3 mRNA and protein expression.
DKK3 is reported to be silenced by promoter CpG methylation in ALL. 11, 23 In this study, 5-AdC treatment increased DKK3 mRNA and protein expression in both cell lines. However, MYCN mRNA and protein levels were significantly decreased in Nalm6 and BALL- Figure 3E ,H) in G1 phase increased from 41.8% to 53.7% and from 37.3% to 45.8%, respectively. In addition, apoptosis assays revealed that MYCN siRNA treatment increased apoptosis but that MYCN overexpression decreased apoptosis of Nalm6 (Figure 3C,I) and BALL-1 ( Figure 3F,J) DKK3 is reported to be a putative antagonist of the Wnt/b-catenin signalling pathway, 7 and activation of this pathway has been implicated in the pathogenesis of leukaemia. [24] [25] [26] To explore the effects of MYCN on the Wnt/b-catenin signalling pathway, we measured the protein levels of p-GSK3b, GSK3b and both cytoplasmic and nuclear b-catenin in Nalm6 and BALL-1 cells by Western blotting. In contrast to DKK3 protein levels ( Figure 2E,F) , the p-GSK3b and nuclear bcatenin protein levels were increased in MYCN-overexpressing cells. 
| DISCUSSION
In this study, we identified MYCN as a strong marker for the onset and progression of adult B-ALL. We provide evidence that MYCN expression is markedly up-regulated in newly diagnosed and relapsed adult B-ALL but is down-regulated in patients who achieve CR.
MYCN overexpression has been reported in haematologic malignancies, such as lymphoma, 27 chronic lymphocytic leukaemia (CLL) 28 and paediatric T-ALL, 29 and it is considered a well-established marker of a poor prognosis in these diseases. In addition, a previous study showed that MYCN overexpression rapidly led to acute myeloid leukaemia (AML) in mice. 30 MYCN was able to induce pre-B-ALL/LBL directly from the progenitor B cells of mice in the absence of Ink4a and Arf. 
| 3635
We confirmed the previously reported inverse relationship between DKK3 and MYCN gene expression in neuroblastic cell lines. 40 MYCN has been shown to directly bind to the promoter of some genes to drive transcription; these genes include SKP2, NDRG1, TG2 and HMGA1. 17, 42 However, previous studies did not find a direct relationship between MYCN and DKK3. Here, we confirmed direct tar- Therefore, we analysed published gene expression data from The
Cancer Genome Atlas and Gene Expression Omnibus, but we did not find abnormal MYCN expression or prognosis-related data for adult B-ALL. Thus, further research with a larger cohort will be needed to assess whether MYCN is predictive for adult B-ALL relapse. In addition, the HDAC inhibitor vorinostat has been shown to down-regulate MYCN mRNA and protein levels in neuroblastoma. [43] [44] [45] In the present study, we confirmed that 5-AdC has a similar effect. We therefore believe that siRNA either alone or in combination with epigenetic drugs may be of potential therapeutic significance for MYCN-amplified adult B-ALL.
